Independent analysis of commercial transformation across life sciences in Europe

Life Sciences Commercial Transformation in Europe — Strategy, Market Signals, and What Comes Next

Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.

Read the Weekly Signal About Piotr Wrzosinski

Weekly Life Sciences Signal

Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.

• Weekly Signal

  Europe Life Sciences Weekly Signal #40: The Bottleneck Moves Downstream

  ByPiotr Wrzosinski 07/06/202607/06/2026

  Week of 1–7 June 2026 This was a week of things being declared ready. Merck arrived at ASCO with a clearer post-Keytruda oncology portfolio story. Brussels set up the expert bodies that will support AI Act enforcement. Semble raised £30m to scale a platform already embedded in UK care delivery. Sanofi brought Biogen into a…

• Weekly Signal

  Europe Life Sciences Weekly Signal #39 Acquiring Is Not Operating

  ByPiotr Wrzosinski 31/05/202631/05/2026

  Week of 25–31 May 2026 Life sciences organisations have never had more ways to acquire capability. They can buy pipelines, license products, enter new geographies through partnerships, deploy increasingly sophisticated AI platforms, or secure access to new markets through regulatory approvals. Capital remains available for the right assets, technology has become easier to access, and…

• Weekly Signal

  Europe Life Sciences Weekly Signal #38: Where Launches Are Really Decided

  ByPiotr Wrzosinski 24/05/202624/05/2026

  Week of 18–24 May 2026 This week looked fragmented at first glance: a US approval for a hypertension medicine, Veeva’s commercial software summit, CHMP opinions on oral Wegovy and biomarker-led oncology, EUDAMED’s approaching deadline, and EMA’s breakthrough device pilot closing its first application window. They are not fragmented. The common thread is upstream commercial design….